Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Frantzi

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Cancers|May 28, 2022
Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene SignatureRafael Stroggilos, Maria Frantzi, Jerome Zoidakis, et al.
World Journal of Urology|July 16, 2022
Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancerMaria Frantzi, Isabel Heidegger, Marie C Roesch, et al.
Cancers|August 12, 2022
Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and AggressivenessVasiliki Lygirou, Konstantinos Fasoulakis, Rafael Stroggilos, et al.
Molecular & Cellular Proteomics : MCP|December 14, 2011
Profilin 1 is a potential biomarker for bladder cancer aggressivenessJerome Zoidakis, Manousos Makridakis, Panagiotis G Zerefos, et al.
Diabetes Research and Clinical Practice|June 26, 2026
Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy: Urinary peptides for diagnosis of nodular DNMargarita Kondyli, Justyna Siwy, Mayra Alejandra Jaimes Campos, et al.
Seminars in Nephrology|January 3, 2018
Proteomics and Metabolomics for AKI DiagnosisDavid Marx, Jochen Metzger, Martin Pejchinovski, et al.
British Journal of Cancer|May 17, 2019
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancerMaria Frantzi, Enrique Gomez Gomez, Ana Blanca Pedregosa, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
Cancers|February 25, 2023
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal ExaminationMaria Frantzi, Zoran Culig, Isabel Heidegger, et al.
Oncotarget|September 30, 2016
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer modelsMaria Frantzi, Zoi Klimou, Manousos Makridakis, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Cancers|May 28, 2022
Gene Expression Monotonicity across Bladder Cancer Stages Informs on the Molecular Pathogenesis and Identifies a Prognostic Eight-Gene SignatureRafael Stroggilos, Maria Frantzi, Jerome Zoidakis, et al.
World Journal of Urology|July 16, 2022
Validation of diagnostic nomograms based on CE-MS urinary biomarkers to detect clinically significant prostate cancerMaria Frantzi, Isabel Heidegger, Marie C Roesch, et al.
Cancers|August 12, 2022
Proteomic Analysis of Prostate Cancer FFPE Samples Reveals Markers of Disease Progression and AggressivenessVasiliki Lygirou, Konstantinos Fasoulakis, Rafael Stroggilos, et al.
Molecular & Cellular Proteomics : MCP|December 14, 2011
Profilin 1 is a potential biomarker for bladder cancer aggressivenessJerome Zoidakis, Manousos Makridakis, Panagiotis G Zerefos, et al.
Diabetes Research and Clinical Practice|June 26, 2026
Urine peptides enable non-invasive differential diagnosis of nodular diabetic nephropathy: Urinary peptides for diagnosis of nodular DNMargarita Kondyli, Justyna Siwy, Mayra Alejandra Jaimes Campos, et al.
Seminars in Nephrology|January 3, 2018
Proteomics and Metabolomics for AKI DiagnosisDavid Marx, Jochen Metzger, Martin Pejchinovski, et al.
British Journal of Cancer|May 17, 2019
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancerMaria Frantzi, Enrique Gomez Gomez, Ana Blanca Pedregosa, et al.
British Journal of Cancer|October 3, 2022
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patientsLourdes Mengual, Maria Frantzi, Marika Mokou, et al.
Cancers|February 25, 2023
Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal ExaminationMaria Frantzi, Zoran Culig, Isabel Heidegger, et al.
Oncotarget|September 30, 2016
Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca2+ signaling in T24M-based bladder cancer modelsMaria Frantzi, Zoi Klimou, Manousos Makridakis, et al.
Pageof 6